Literature DB >> 16580316

Maternal-fetal surgery for myelomeningocele: neurodevelopmental outcomes at 2 years of age.

Mark Paul Johnson1, Marsha Gerdes, Natalie Rintoul, Patrick Pasquariello, Jeanne Melchionni, Leslie N Sutton, N Scott Adzick.   

Abstract

OBJECTIVE: This study was undertaken to examine short-term neurodevelopmental outcomes in children with myelomeningocele (MMC) who underwent in utero neurosurgical closure. STUDY
DESIGN: Between 1998 and 2002, 51 fetuses underwent in utero MMC closure at our Center. Thirty (63%) of these children have returned for neurodevelopmental testing at 2 years of age using the Bayley Scales of Infant Development and Preschool Language Scales.
RESULTS: Overall shunt rate was 43% in this group. Neurodevelopmental testing found 67% with cognitive language and personal-social skills in the normal range, 20% with mild delays, and 13% with significant delays. Children with shunted hydrocephalus scored lower than those with unshunted ventriculomegaly.
CONCLUSION: Children who have undergone fetal MMC closure have characteristic neurodevelopmental deficits that do not appear worsened by fetal surgery, and developmental outcomes may be improved by decreasing the need for ventriculoperitoneal shunting.

Entities:  

Mesh:

Year:  2006        PMID: 16580316     DOI: 10.1016/j.ajog.2006.01.072

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  21 in total

1.  In utero Repair of Myelomeningocele: Rationale, Initial Clinical Experience and a Randomized Controlled Prospective Clinical Trial.

Authors:  Enrico Danzer; Alan W Flake
Journal:  Neuroembryology Aging       Date:  2008-02-26

2.  Fetal surgery: the ochsner experience with in utero spina bifida repair.

Authors:  Lora Kahn; Nnenna Mbabuike; Edison P Valle-Giler; Juanita Garces; R Clifton Moore; Hugo St Hilaire; Cuong J Bui
Journal:  Ochsner J       Date:  2014

3.  Chiari I malformation and altered cerebrospinal fluid dynamics-the highs and the lows.

Authors:  Soumya Mukherjee; Neeraj Kalra; Daniel Warren; Gnanamurthy Sivakumar; John R Goodden; Atul K Tyagi; Paul D Chumas
Journal:  Childs Nerv Syst       Date:  2019-06-16       Impact factor: 1.475

4.  Intrauterine myelomeningocele repair postnatal results and follow-up at 3.5 years of age--initial experience from a single reference service in Brazil.

Authors:  Wagner Jou Hisaba; Sérgio Cavalheiro; Carlos Gilberto Almodim; Carolina Peixoto Borges; Tereza Cristina Carbonari de Faria; Edward Araujo Júnior; Luciano Marcondes Machado Nardozza; Antonio Fernandes Moron
Journal:  Childs Nerv Syst       Date:  2011-12-29       Impact factor: 1.475

Review 5.  Fetal surgery for myelomeningocele is effective: a critical look at the whys.

Authors:  Martin Meuli; Ueli Moehrlen
Journal:  Pediatr Surg Int       Date:  2014-06-08       Impact factor: 1.827

Review 6.  Fetal surgery for neural tube defects.

Authors:  Leslie N Sutton
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2007-08-22       Impact factor: 5.237

7.  Brain malformations in the sheep model of myelomeningocele are similar to those found in human disease: preliminary report.

Authors:  Jose Luis Encinas Hernández; C Soto; M A García-Cabezas; F Pederiva; M Garriboli; R Rodríguez; J L Peiró; F Carceller; M López-Santamaría; J A Tovar
Journal:  Pediatr Surg Int       Date:  2008-12       Impact factor: 1.827

8.  Congenital myelomeningocele - do we have to change our management?

Authors:  Steffi Mayer; Margit Weisser; Holger Till; Gerd Gräfe; Christian Geyer
Journal:  Cerebrospinal Fluid Res       Date:  2010-10-14

Review 9.  Fetal surgery for spina bifida: past, present, future.

Authors:  N Scott Adzick
Journal:  Semin Pediatr Surg       Date:  2013-02       Impact factor: 2.754

10.  Congenital malformations of the central nervous system: clinical approach.

Authors:  Feriha Hadzagić-Catibusić; Hajrija Maksić; Sajra Uzicanin; Suada Heljić; Smail Zubcević; Zulejha Merhemić; Adisa Cengić; Edina Kulenović
Journal:  Bosn J Basic Med Sci       Date:  2008-11       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.